Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EyePoint Pharmaceuticals (EYPT) Cash from Financing Activities: 2011-2019

Historic Cash from Financing Activities for EyePoint Pharmaceuticals (EYPT) over the last 4 years, with Dec 2019 value amounting to -$7.0 million.

  • EyePoint Pharmaceuticals' Cash from Financing Activities rose 86.91% to -$7.0 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$19.8 million, marking a year-over-year decrease of 137.60%. This contributed to the annual value of $164.0 million for FY2024, which is 12.32% down from last year.
  • Per EyePoint Pharmaceuticals' latest filing, its Cash from Financing Activities stood at -$7.0 million for Q4 2019, which was down 159.94% from $11.6 million recorded in Q1 2019.
  • Over the past 5 years, EyePoint Pharmaceuticals' Cash from Financing Activities peaked at $53.6 million during Q2 2018, and registered a low of -$53.3 million during Q4 2018.
  • For the 3-year period, EyePoint Pharmaceuticals' Cash from Financing Activities averaged around $7.3 million, with its median value being $6.1 million (2017).
  • As far as peak fluctuations go, EyePoint Pharmaceuticals' Cash from Financing Activities soared by 10,600.00% in 2017, and later slumped by 976.27% in 2018.
  • Over the past 5 years, EyePoint Pharmaceuticals' Cash from Financing Activities (Quarterly) stood at $329,000 in 2015, then remained steady at $9,000 in 2016, then spiked by 10,600.00% to $6.1 million in 2017, then plummeted by 976.27% to -$53.3 million in 2018, then spiked by 86.91% to -$7.0 million in 2019.
  • Its last three reported values are -$7.0 million in Q4 2019, $11.6 million for Q1 2019, and -$53.3 million during Q4 2018.